glp-1 obesity drugs news today 2025 Amgen Reshapes the Drug Market with Innovative MariTide Americans turn to risky unregulated
Description
18 Nevertheless, the 2018 ADA Standards of Care lists alogliptin as having a potential HF risk
others do not test at all
Chinese companies are increasingly shaping the innovation landscape
The remaining trials (TRIUMPH-2/-3/-4 and TRIUMPH-Outcomes) are still anticipated through 20262028
Not a weight loss program
Among other things, there can be no guarantee that future study results will be consistent with the results to date or that GIP/GLP-1 RA will achieve its primary study endpoints or receive regulatory approvals
